382 related articles for article (PubMed ID: 13679475)
1. Sevelamer hydrochloride, a phosphate binder, protects against deterioration of renal function in rats with progressive chronic renal insufficiency.
Nagano N; Miyata S; Obana S; Kobayashi N; Fukushima N; Burke SK; Wada M
Nephrol Dial Transplant; 2003 Oct; 18(10):2014-23. PubMed ID: 13679475
[TBL] [Abstract][Full Text] [Related]
2. Sevelamer hydrochloride (Renagel), a non-calcaemic phosphate binder, arrests parathyroid gland hyperplasia in rats with progressive chronic renal insufficiency.
Nagano N; Miyata S; Obana S; Ozai M; Kobayashi N; Fukushima N; Burke SK; Wada M
Nephrol Dial Transplant; 2001 Sep; 16(9):1870-8. PubMed ID: 11522872
[TBL] [Abstract][Full Text] [Related]
3. Sevelamer hydrochloride reverses parathyroid gland enlargement via regression of cell hypertrophy but not apoptosis in rats with chronic renal insufficiency.
Nagano N; Miyata S; Abe M; Wakita S; Kobayashi N; Wada M
Nephrol Dial Transplant; 2006 Mar; 21(3):634-43. PubMed ID: 16169864
[TBL] [Abstract][Full Text] [Related]
4. Sevelamer hydrochloride prevents ectopic calcification and renal osteodystrophy in chronic renal failure rats.
Katsumata K; Kusano K; Hirata M; Tsunemi K; Nagano N; Burke SK; Fukushima N
Kidney Int; 2003 Aug; 64(2):441-50. PubMed ID: 12846739
[TBL] [Abstract][Full Text] [Related]
5. [Sevelamer hydrochloride prevents ectopic calcification of blood vessels].
Fukushima N; Nagano N
Clin Calcium; 2004 Jun; 14(6):116-22. PubMed ID: 15577065
[TBL] [Abstract][Full Text] [Related]
6. Determinants of progressive vascular calcification in haemodialysis patients.
Chertow GM; Raggi P; Chasan-Taber S; Bommer J; Holzer H; Burke SK
Nephrol Dial Transplant; 2004 Jun; 19(6):1489-96. PubMed ID: 15102961
[TBL] [Abstract][Full Text] [Related]
7. Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia.
Cozzolino M; Staniforth ME; Liapis H; Finch J; Burke SK; Dusso AS; Slatopolsky E
Kidney Int; 2003 Nov; 64(5):1653-61. PubMed ID: 14531797
[TBL] [Abstract][Full Text] [Related]
8. [Effects of intermittent treatment with sevelamer hydrochloride on parathyroid hyperplasia and vascular calcification in rats with chronic kidney disease].
Nagano N; Miyata S; Abe M; Wakita S; Kobayashi N; Wada M
Clin Calcium; 2005 Sep; 15 Suppl 1():35-9; discussion 39-40. PubMed ID: 16272627
[TBL] [Abstract][Full Text] [Related]
9. The effects of sevelamer hydrochloride and calcium carbonate on kidney calcification in uremic rats.
Cozzolino M; Dusso AS; Liapis H; Finch J; Lu Y; Burke SK; Slatopolsky E
J Am Soc Nephrol; 2002 Sep; 13(9):2299-308. PubMed ID: 12191974
[TBL] [Abstract][Full Text] [Related]
10. Influence of sevelamer hydrochloride on serum concentration of whole (1-84) and N-terminally truncated (7-84) parathyroid hormone fragments in hemodialysis uremic patients.
Chudek J; Piecha G; Kokot F; Wiecek A
J Nephrol; 2003; 16(5):710-5. PubMed ID: 14733418
[TBL] [Abstract][Full Text] [Related]
11. Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis.
Raggi P; James G; Burke SK; Bommer J; Chasan-Taber S; Holzer H; Braun J; Chertow GM
J Bone Miner Res; 2005 May; 20(5):764-72. PubMed ID: 15824849
[TBL] [Abstract][Full Text] [Related]
12. The interaction of PTH and dietary phosphorus and calcium on serum calcitriol levels in the rat with experimental renal failure.
Martin-Malo A; Rodriguez M; Martinez ME; Torres A; Felsenfeld AJ
Nephrol Dial Transplant; 1996 Aug; 11(8):1553-8. PubMed ID: 8856210
[TBL] [Abstract][Full Text] [Related]
13. Sevelamer hydrochloride, a calcium-free phosphate binder, inhibits parathyroid cell proliferation in partially nephrectomized rats.
Nagano N; Miyata S; Obana S; Kobayashi N; Abe M; Fukushima N; Wada M
Nephrol Dial Transplant; 2003 Jun; 18 Suppl 3():iii81-5. PubMed ID: 12771309
[TBL] [Abstract][Full Text] [Related]
14. Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rats.
Nagano N; Miyata S; Abe M; Kobayashi N; Wakita S; Yamashita T; Wada M
Kidney Int; 2006 Feb; 69(3):531-7. PubMed ID: 16395276
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of sevelamer. Comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients.
Shaheen FA; Akeel NM; Badawi LS; Souqiyyeh MZ
Saudi Med J; 2004 Jun; 25(6):785-91. PubMed ID: 15195212
[TBL] [Abstract][Full Text] [Related]
16. Meta-analysis of the effect of sevelamer on phosphorus, calcium, PTH, and serum lipids in dialysis patients.
Burke SK; Dillon MA; Hemken DE; Rezabek MS; Balwit JM
Adv Ren Replace Ther; 2003 Apr; 10(2):133-45. PubMed ID: 12879374
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and side-effect profile of sevelamer hydrochloride used in combination with conventional phosphate binders.
Sturtevant JM; Hawley CM; Reiger K; Johnson DW; Campbell SB; Burke JR; Bofinger A; Isbel NM
Nephrology (Carlton); 2004 Dec; 9(6):406-13. PubMed ID: 15663645
[TBL] [Abstract][Full Text] [Related]
18. Sevelamer reduces calcium load and maintains a low calcium-phosphorus ion product in dialysis patients.
Gallieni M; Cozzolino M; Carpani P; Zoni U; Brancaccio D
J Nephrol; 2001; 14(3):176-83. PubMed ID: 11439741
[TBL] [Abstract][Full Text] [Related]
19. Nicotinamide prevents the development of hyperphosphataemia by suppressing intestinal sodium-dependent phosphate transporter in rats with adenine-induced renal failure.
Eto N; Miyata Y; Ohno H; Yamashita T
Nephrol Dial Transplant; 2005 Jul; 20(7):1378-84. PubMed ID: 15870221
[TBL] [Abstract][Full Text] [Related]
20. Sevelamer with and without calcium and vitamin D: observations from a long-term open-label clinical trial.
Chertow GM; Dillon MA; Amin N; Burke SK
J Ren Nutr; 2000 Jul; 10(3):125-32. PubMed ID: 10921533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
